The importance of this mechanism has been inferred in models of pancreatic and breast cancer in which inhibition of CXCR4 using a clinically approved inhibitor (AMD3100) increased intratumoural T cell accumulation and response to checkpoint inhibition (Chen et al., 2019). This evidence concerns the gene CXCR4 and breast carcinoma.